About IO Biotech
We are a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on our T-win technology platform.
Our product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
We aim to disrupt the way cancer is treated with our approach, solidifying our product candidates as the cornerstones for multiple solid tumors.
Leadership
We have assembled a seasoned management team with extensive experience in developing novel oncology therapies, including advancing product candidates from preclinical research through to clinical development, and ultimately to regulatory approval.
Mai-Britt Zocca, Ph.D.
Founder, Chief Executive Officer
Keith Vendola, MD MBA
Chief Financial Officer
Eva Ehrnrooth, M.D., Ph.D.
Chief Medical Officer
Muhammad Al-Hajj, Ph.D.
Chief Scientific Officer
Mikkel Dybkjaer, MSc
VP Corporate Finance
Andrew Willis
SVP, Regulatory, CMC & Quality
Ayako Wakatsuki Pedersen, Ph. D.
VP, Translational Research
Board of Directors
Our board of directors has deep expertise in the fields of immuno-oncology, business and finance.
Peter Hirth, Ph.D.
Chairman
Kathleen Sereda Glaub, M.B.A.
Member
Christian Elling, Ph.D.
Member – Lundbeckfonden
Emmanuelle Coutanceau, Ph.D.
Member – Novo Holdings
Claus Andersson, Ph.D.
Member - Sunstone Life Science Ventures
Priyanka Belawat, Ph.D.
Member – HBM Healthcare Investments
Jack B. Nielsen, M. Sc.
Member - Vivo Capital
Vanessa Malier
Member – Kurma Partners
Scientific Advisory Board
Kapil Dhingra, MD, Ph.D.
Strategic R&D Advisor
Professor Mads Hald Andersen, MD, Ph.D.
Founder, Scientific Advisor
Professor, MD, Ph.D. Inge Marie Svane
Founder, Clinical Advisor
Alexander Eggermont, MD, PhD, Professor
Clinical advisor